Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(6/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(6/week)
News
United States
(507/week)
Manufacturing
(335/week)
Energy
(278/week)
Technology
(347/week)
Other Energy
(240/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Samidorphan
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Jul 15, 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Feb 01, 2019
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
Nov 29, 2018
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Nov 01, 2018
Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
Nov 01, 2018
Trading in Alkermes Ordinary Shares Halted Today
Oct 29, 2018
Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
May 03, 2018
Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program
Apr 26, 2018
Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia
Apr 16, 2018
Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
Apr 02, 2018
Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
Jan 31, 2018
Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder
Latest News
Apr 19, 2024
ICE Announces Record Trading Activity in Murban Crude as ICE Futures Abu Dhabi Marks Third Anniversary
Apr 19, 2024
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
Apr 19, 2024
Two Top Rating Agencies Reaffirm Metropolitan’s Strong Credit Ratings
Apr 19, 2024
Mativ Announces Conference Call to Discuss First Quarter 2024 Results
Apr 19, 2024
LSI Industries Acquires EMI Industries, Expanding Store Fixtures and Food Service Equipment Business
Apr 19, 2024
Anue Water Technologies Adds Four New Channel Partners to Serve Wastewater Treatment Customers in California...
Apr 19, 2024
Kermit Facility Operational Update
Apr 19, 2024
Russia says crew member killed in bomber crash
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events